Predictors of lethal outcome in patients with immunoinflammatory diseases hospitalized in the intensive care unit

Table 1 Demographic characteristics, treatments, and outcomes of patients with immunoinflammatory diseases hospitalized in the intensive care unit

Parameter	n = 51
Demographics
Sex, males	23 (45.1)
Age, months, median (25%; 75%)	121 (60; 182)
Disease groups
MIS-C	18 (35.3)
Systemic rheumatic diseases	24 (47.1)
Infections	9 (17.6)
Time to ICU admission from the diagnosis of the disease, days, median (25%; 75%)	10.0 (6.0; 30.0)
Treatment
Preceding IST	14 (27.5)
IST started in ICU	29 (56.9)
Follow-up IST in ICU	43 (84.3)
Outcomes
Duration of stay in ICU, days, median (25%; 75%)	6.0 (4.0; 17.0)
Total hospital staying, days, median (25%; 75%)	24.0 (16.0; 44.0)
Lethal outcome	13 (25.5)
Days before death, median (25%; 75%)	39 (17; 62)

Data presented as n (%). ICU: Intensive care unit; IST: Immune-suppressive treatment; MIS-C: Multisystem inflammatory syndrome associated with coronavirus disease 2019 in children.